Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8886558 | 1.00 | LTA4H (0.47) | LTA4HADRB2ADRB1ADRB3NPC1 | |
| Hydrochloric Acid SCHEMBL27586224 | 0.99 | LTA4H (0.46) | LTA4HADRB2ADRB1ADRB3NPC1 | |
| Hydrochloric Acid SCHEMBL5759568 | 0.99 | LTA4H (0.46) | LTA4HADRB2ADRB1ADRB3NPC1 | |
| SCHEMBL18025353 | 0.87 | CA12 (0.44) | LTA4HADRB2ADRB1ADRB3NPC1 | |
| SCHEMBL25937506 | 0.87 | NPC1 (0.47) | ADRB2ADRB1ADRB3NPC1RAB9A | |
| SCHEMBL12710300 | 0.86 | LTA4H (0.47) | LTA4HALDH1A1ITGB3ITGA2BPTGS2 | |
| SCHEMBL15697332 | 0.85 | ADRB2 (0.45) | LTA4HADRB2ADRB1ADRB3NPC1 | |
| SCHEMBL18774800 | 0.84 | CYP2D6 (0.47) | LTA4HADRB2ADRB1ADRB3NPC1 | |
| SCHEMBL8404165 | 0.84 | CYP2D6 (0.47) | LTA4HADRB2ADRB1ADRB3NPC1 | |
| SCHEMBL524638 | 0.84 | ITGB3 (0.59) | NPC1RAB9AMAPTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | WASHINGTON UNIVERSITY | 2025-05-29 | — | — | US | disclosed |
| US-5643784-A | TREATMENT OF ANXIETY, DEPRESSION, SLEEPING DISORDERS, SCHIZOPHRENIA AND MIGRAINE | H, LUNDBECK A/S (DK) | 1997-07-01 | — | — | US | disclosed |
| US-5599926-A | PEPTIDE BONDING PROPERTIES MAKE IT USEFUL IN PURIFICATION PROCESSES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1995020590-A1 | ENANTIOSELECTIVE RECEPTORS FOR AMINO ACID DERIVATIVES, AND OTHER COMPOUNDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1995-08-03 | — | — | WO | disclosed |
| EP-0560868-B1 | INDAN DERIVATIVES | LUNDBECK & CO AS H (DK) | 1995-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | TMPRSS2, PRSS1, PRSS2 | LTA4H 2097/4885ADRB2 4528/4885ADRB1 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.